Comparing two treatments for small liver cancer in patients with low albumin levels

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares the effectiveness of 90-Yttrium Therasphere transarterial radioembolization (90Y) and microwave ablation (MWA) in patients diagnosed with small, early-stage hepatocellular carcinoma (HCC) who also have hypoalbuminemia. The study focuses on patients with a single tumor of 3 cm or less and aims to determine which treatment lowers the risk of disease progression within the first year after diagnosis. Participants will be randomly assigned to receive either 90Y or MWA as their initial treatment, followed by standard care. The trial will enroll 50 participants and will track their outcomes over a one-year observational period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HCC diagnosis according to the Liver Imaging - Reporting Data System (LI-RADS) Criteria as defined in the American Association for the Study of Liver Diseases 2018 HCC practice guidelines
* Eastern Cooperative Oncology Group score 0 - 1
* Child-Pugh A - B
* Bilirubin \< 2.5 mg/dL
* Creatinine \< 2.0 mg/dL
* No prior liver-directed therapy or systemic therapy for HCC
* Solitary, unresectable HCC ≤ 3cm
* Albumin level \< 3.4 g/dL at HCC diagnosis
* Tumor anatomical location and angiosome amendable to MWA and 90Y

Exclusion Criteria:

* Pregnant women
* Concurrent malignancy

Where it's running

• Ochsner Main Campus
  New Orleans, Louisiana, United States Recruiting

Study contacts

• Principal investigator: Ari Cohen, MD — Ochsner Health
• Study coordinator: Ken Bode
• Email: ken.bode@ochsner.org
• Phone: 5048421936

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• Irpagratinib plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma with FGF19 overexpression

  This trial will test whether adding irpagratinib to atezolizumab and bevacizumab helps people with advanced or unresectable hepatocellular carcinoma whose tumors overexpress FGF19.

  Recruiting Phase 2 Asan Medical Center · Seoul and 2 other locations · NCT07010497

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

• Evaluating HLX43 for advanced liver cancer patients who can't tolerate standard treatments

  This study is testing a new treatment called HLX43 for people with advanced liver cancer who can't handle standard therapies to see if it helps them.

  Recruiting Phase 2 Shanghai Henlius Biotech · Hunan, Hunan · NCT06742892

• Evaluating AST-201 for GPC3-positive advanced solid tumors

  This study is testing a new treatment called AST-201 to see if it can help people with advanced solid tumors that have a specific marker called GPC3.

  Recruiting at 4 sites Phase 1 Aptamer Sciences, Inc. · Goyang-si, Gyeonggi-do and 3 other locations · NCT06687941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.